1. age \< 18 2. pregnant 3. allergic to experimental drugs 4. the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); 5. copd or end-stage lung disease requires home oxygen therapy 6. expected survival time not exceeding 48 hours 7. participated in other clinical intervention trials within the last 3 months 8. autoimmune diseases 9. a history of organ, bone marrow or hematopoietic stem cell transplantation 10. received radiotherapy and chemotherapy for malignant tumor within 6 months 11.hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells \<=200/mm3) 12. patients receiving anti-hcv treatment 13.90 days of retinal detachment or eye surgery 14. permanent blindness in one eye 15. history of iritis, endophthalmitis, scleral inflammation or retinitis 16. the competent physician considered it inappropriate to participate in the study

1. age \< 18 2. pregnant 3. allergic to experimental drugs 4. the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); 5. copd or end-stage lung disease requires home oxygen therapy 6. expected survival time not exceeding 48 hours 7. participated in other clinical intervention trials within the last 3 months 8. autoimmune diseases 9. a history of organ, bone marrow or hematopoietic stem cell transplantation 10. received radiotherapy and chemotherapy for malignant tumor within 6 months 11.hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells \<=200/mm3) 12. patients receiving anti-hcv treatment 13.90 days of retinal detachment or eye surgery 14. permanent blindness in one eye 15. history of iritis, endophthalmitis, scleral inflammation or retinitis 16. the competent physician considered it inappropriate to participate in the study

age < 18 pregnant allergic to experimental drugs the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); copd or end-stage lung disease requires home oxygen therapy expected survival time not exceeding 48 hours participated in other clinical intervention trials within the last 3 months autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation 10. received radiotherapy and chemotherapy for malignant tumor within 6 months 11.hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells <=200/mm3) 12. patients receiving anti-hcv treatment 13.90 days of retinal detachment or eye surgery 14. permanent blindness in one eye 15. history of iritis, endophthalmitis, scleral inflammation or retinitis 16. the competent physician considered it inappropriate to participate in the study

age < 18 pregnant allergic to experimental drugs the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); copd or end-stage lung disease requires home oxygen therapy expected survival time not exceeding 48 hours participated in other clinical intervention trials within the last 3 months autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation 10. received radiotherapy and chemotherapy for malignant tumor within 6 months 11.hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells <=200/mm3) 12. patients receiving anti-hcv treatment 13.90 days of retinal detachment or eye surgery 14. permanent blindness in one eye 15. history of iritis, endophthalmitis, scleral inflammation or retinitis 16. the competent physician considered it inappropriate to participate in the study

1. age < 18 2. pregnant 3. allergic to experimental drugs 4. the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); 5. copd or end-stage lung disease requires home oxygen therapy 6. expected survival time not exceeding 48 hours 7. participated in other clinical intervention trials within the last 3 months 8. autoimmune diseases 9. a history of organ, bone marrow or hematopoietic stem cell transplantation 10. received radiotherapy and chemotherapy for malignant tumor within 6 months 11.hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells <=200/mm3) 12. patients receiving anti-hcv treatment 13.90 days of retinal detachment or eye surgery 14. permanent blindness in one eye 15. history of iritis, endophthalmitis, scleral inflammation or retinitis 16. the competent physician considered it inappropriate to participate in the study

1. age < 18 2. pregnant 3. allergic to experimental drugs 4. the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); 5. copd or end-stage lung disease requires home oxygen therapy 6. expected survival time not exceeding 48 hours 7. participated in other clinical intervention trials within the last 3 months 8. autoimmune diseases 9. a history of organ, bone marrow or hematopoietic stem cell transplantation 10. received radiotherapy and chemotherapy for malignant tumor within 6 months 11.hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells <=200/mm3) 12. patients receiving anti-hcv treatment 13.90 days of retinal detachment or eye surgery 14. permanent blindness in one eye 15. history of iritis, endophthalmitis, scleral inflammation or retinitis 16. the competent physician considered it inappropriate to participate in the study